United States - English - NLM (National Library of Medicine)

bristol-myers squibb pharma company - warfarin sodium (unii: 6153cwm0cl) (warfarin - unii:5q7zvv76ei) - warfarin sodium 1 mg - coumadin® is indicated for: limitations of use coumadin has no direct effect on an established thrombus, nor does it reverse ischemic tissue damage. once a thrombus has occurred, however, the goals of anticoagulant treatment are to prevent further extension of the formed clot and to prevent secondary thromboembolic complications that may result in serious and possibly fatal sequelae. coumadin is contraindicated in: • pregnancy coumadin is contraindicated in women who are pregnant except in pregnant women with mechanical heart valves, who are at high risk of thromboembolism [see warnings and precautions (5.7) and use in specific populations (8.1)] . coumadin can cause fetal harm when administered to a pregnant woman. coumadin exposure during pregnancy causes a recognized pattern of major congenital malformations (warfarin embryopathy and fetotoxicity), fatal fetal hemorrhage, and an increased risk of spontaneous abortion and fetal mortality. if coumadin is used during pregnancy or if the patient becomes pregn

United States - English - NLM (National Library of Medicine)

zhejiang yasili cosmetics co. ltd - alcohol (unii: 3k9958v90m) (alcohol - unii:3k9958v90m) - antiseptic, hand sanitizer hand sanitizer to help reduce bacteria on the skin.

United States - English - NLM (National Library of Medicine)

midland products llc - alcohol (unii: 3k9958v90m) (alcohol - unii:3k9958v90m) - antiseptic, hand sanitizer hand sanitizer to help reduce bacteria that potentially can cause disease. for use when soap and water are not available. - in children less than 2 months of age - on open skin wounds stop use and ask a doctor if irritation or rash occurs. these may be signs of a serious condition.

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - desogestrel 75 µg - film-coated tablet - 75 µg - desogestrel 75 µg - desogestrel

United States - English - NLM (National Library of Medicine)

e. fougera & co. a division of fougera pharmaceuticals inc. - methscopolamine bromide (unii: rtn51lk7wl) (methscopolamine - unii:vdr09vtq8u) - methscopolamine bromide 2.5 mg - adjunctive therapy for the treatment of peptic ulcer. methscopolamine bromide has not been shown to be effective in contributing to the healing of peptic ulcer, decreasing the rate of recurrence or preventing complications. glaucoma; obstructive uropathy (e.g., bladder neck obstruction due to prostatic hypertrophy); obstructive disease of the gastrointestinal tract (e.g., pyloroduodenal stenosis); paralytic ileus; intestinal atony of the elderly or debilitated patient; unstable cardiovascular status in acute hemorrhage; severe ulcerative colitis; toxic megacolon complicating ulcerative colitis; myasthenia gravis. methscopolamine bromide 2.5 mg tablets/methscopolamine bromide 5 mg tablets are contraindicated in patients who are hypersensitive to methscopolamine bromide or related drugs. not applicable.

United States - English - NLM (National Library of Medicine)

e. fougera & co. a division of fougera pharmaceuticals inc. - alclometasone dipropionate (unii: s56pql4n1v) (alclometasone - unii:136h45tb7b) - alclometasone dipropionate 0.5 mg in 1 g - alclometasone dipropionate cream is a low to medium potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. alclometasone dipropionate cream may be used in pediatric patients 1 year of age or older, although the safety and efficacy of drug use for longer than 3 weeks have not been established (see precautions: pediatric use ). since the safety and efficacy of alclometasone dipropionate cream have not been established in pediatric patients below 1 year of age, the use in this age-group is not recommended. alclometasone dipropionate cream is contraindicated in those patients with a history of hypersensitivity to any of the components in these preparations.

United States - English - NLM (National Library of Medicine)

e. fougera & co. a division of fougera pharmaceuticals inc. - diclofenac sodium (unii: qtg126297q) (diclofenac - unii:144o8ql0l1) - diclofenac sodium 30 mg in 1 g - diclofenac sodium gel is indicated for the topical treatment of actinic keratoses (ak). sun avoidance is indicated during therapy. diclofenac sodium gel is contraindicated in patients with a known hypersensitivity to diclofenac, benzyl alcohol, polyethylene glycol monomethyl ether 350 and/or hyaluronate sodium. diclofenac sodium gel is contraindicated in the following patients: - in the setting of coronary artery bypass graft (cabg) surgery.

United States - English - NLM (National Library of Medicine)

e. fougera & co. a division of fougera pharmaceuticals inc. - imiquimod (unii: p1qw714r7m) (imiquimod - unii:p1qw714r7m) - imiquimod 50 mg in 1 g - imiquimod cream is indicated for the topical treatment of clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses on the face or scalp in immunocompetent adults. imiquimod cream is indicated for the treatment of external genital and perianal warts/condyloma acuminata in patients 12 years old or older. imiquimod cream has been evaluated in children ages 2 to 12 years with molluscum contagiosum and these studies failed to demonstrate efficacy [see use in specific populations (8.4) ]. the safety and efficacy of imiquimod cream in immunosuppressed patients have not been established. imiquimod cream should be used with caution in patients with pre-existing autoimmune conditions. the efficacy and safety of imiquimod cream have not been established for patients with basal cell nevus syndrome or xeroderma pigmentosum. none. pregnancy category c: note: the maximum recommended human dose (mrhd) was set at 2 packets per treatment of imiquimod cream (25 mg imiquimod) for the animal multiple of human ex

United States - English - NLM (National Library of Medicine)

e. fougera & co. a division of fougera pharmaceuticals inc. - terconazole (unii: 0kj2ve664u) (terconazole - unii:0kj2ve664u) - terconazole 8 mg in 1 g - terconazole vaginal cream 0.8% is indicated for the local treatment of vulvovaginal candidiasis (moniliasis). as terconazole vaginal cream 0.8% is effective only for vulvovaginitis caused by the genus candida, the diagnosis should be confirmed by koh smears and/or cultures. patients known to be hypersensitive to terconazole or to any of the components of the cream.

United States - English - NLM (National Library of Medicine)

e. fougera & co. a division of fougera pharmaceuticals inc. - clindamycin phosphate (unii: eh6d7113i8) (clindamycin - unii:3u02el437c) - clindamycin 10 mg in 1 ml - clindamycin phosphate topical solution, clindamycin phosphate gel, and clindamycin phosphate lotion are indicated in the treatment of acne vulgaris. in view of the potential for diarrhea, bloody diarrhea and pseudomembranous colitis, the physician should consider whether other agents are more appropriate (see contraindications , warnings and adverse reactions ). clindamycin phosphate topical solution, clindamycin phosphate gel, and clindamycin phosphate lotion are contraindicated in individuals with a history of hypersensitivity to preparations containing clindamycin or lincomycin, a history of regional enteritis or ulcerative colitis, or a history of antibiotic-associated colitis.